Please assess the completion status of the following clinical trial:

Trial Title: A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
SCD Key Inclusion Criteria:~* Must be between 12 and 65 years of age~* Previously diagnosed sickle cell disease (hemoglobin electrophoresis or genotype)~* Must have a minimum body weight of 40 kg (88 lbs) at the Screening Visit~* Must have the ability to understand and sign written informed consent (and assent where applicable), which must be obtained prior to any study-related procedures being completed~* All male and female patients of child bearing potential must agree to use medically accepted contraceptive regimen during study participation and for 90 days after last study drug administration~* Must be willing to abide by all study requirements and restrictions~SCD Key Exclusion Criteria:~* Had more than 6 episodes of vaso-occlusive crisis (VOC) within the past 12 months that required a hospital, emergency room, or clinic visit~* Had a least one episode of acute chest syndrome in the last 6 months~* Received any of the following approved therapies for use in SCD:~  * Hydroxurea (HU): excluded if started HU \< 90 days prior to Day 1 of study treatment~ * Adakveo®: excluded if received an infusion within 14 days prior to Day 1 of study treatment~ * Oxbryta®: excluded if received a dose within 7 days prior to start of Day 1 of study treatment~* Received a red blood cell transfusion within 30 days of starting the study drug~* Hemoglobin \< 7.0 g/dL or \> 10.5 g/dL~* Unable to take and absorb oral medications~HEALTHY VOLUNTEER Inclusion Criteria: \[Note: no longer recruiting subjects for this portion of the study\]~* Subjects must be between 18 and 60 years of age~* Subjects must have the ability to understand and sign written informed consent, which must be obtained prior to any study-related procedures being completed~* Subjects must be in general good health, based upon the results of medical history, a physical examination, vital signs, laboratory profile, and a 12-lead ECG~* All males and females of child bearing potential must agree to use medically accepted contraceptive regimen during study participation and up to 90 days after~* Subjects must be willing to abide by all study requirements and restrictions~HEALTHY VOLUNTEER Exclusion Criteria: \[Note: no longer recruiting subjects for this portion of the study\]~* Evidence of clinically significant medical condition or other condition that might significantly interfere with the absorption, distribution, metabolism, or excretion of study drug, or place the subject at an unacceptable risk as a participant in this study~* History of clinically significant cardiac diseases including condition disturbances~* Abnormal hematologic, renal and liver function studies~* History of drug or alcohol abuse

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Single ascending dose cohorts in healthy subjects (Type: EXPERIMENTAL): Healthy volunteer subject cohorts randomized 6:2 receiving a single dose of FT-4202 or placebo. The first cohort will receive 200 mg of FT-4202 or placebo. Dose escalation will occur if FT-4202 or placebo is tolerated. The maximum dose of FT-4202 or placebo will be 1500 mg.
- Multiple ascending dose cohorts in healthy subjects (Type: EXPERIMENTAL): Healthy volunteer subject cohorts randomized 9:3 to receive FT-4202 or placebo for 14 days continuous dosing. The first cohort will receive 100 mg of FT-4202 or placebo daily X 14 days. The maximum dose of FT-4202/placebo will be 600 mg FT-4202/placebo daily for 14 days.
- Food Effect Cohort in healthy subjects (Type: EXPERIMENTAL): Health Volunteer subject cohort of 10 subjects who will receive a single dose of FT-4202 with food and without food. Dose will be administered per the protocol defined dose.
- Single ascending dose cohorts in SCD subjects (Type: EXPERIMENTAL): Sickle cell disease subject cohort randomized 6:2 receiving a single dose of FT-4202 or placebo. The dose of FT-4202/placebo administered will be a dose that was found to be safe in healthy subjects.
- Multiple ascending dose cohorts in SCD subjects (Type: EXPERIMENTAL): Sickle cell disease subject cohorts randomized 9:3 to receive FT-4202 or placebo for 14 days continuous dosing. The dose of FT-4202/placebo administered will be a dose less than the maximum tolerable dose evaluated in MAD healthy volunteers.
- 12-week dosing cohort in SCD subjects (Type: EXPERIMENTAL): Sickle cell disease subjects cohort to receive up to 84 consecutive daily doses of open-label FT-4202. The dose of FT-4202 administered will not exceed the highest dose evaluated in the MAD SCD subject cohorts

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete